Our proprietary MeltDose® technology has been designed to enhance the release and absorption of drug substances in the body by incorporating soluble forms of the drug in a tablet matrix.
Independent studies have shown that approximately 30% of existing drugs have suboptimal uptake and absorption due to low water-solubility. We believe that a large number of these drugs may be suitable candidates for our MeltDose® reformulation technology. MeltDose® may also be of value for new drugs for which low absorption of a particular drug presents a significant barrier to its final formulation and ultimately its development as an actual drug.
We believe the enhanced release and absorption (improved bioavailability) achieved by our MeltDose® technology may not only increase the effectiveness of these drugs but may also reduce their adverse side effects. Reduction of side effects would happen through decreased variability in the absorption of the drug, e.g. the interaction between food intake and degree of absorption and certain other dosing constraints.
A large number of drugs on the market today would benefit from less variability in the absorption of the drug, as relatively high absorption often results in severe adverse side effects and relatively low absorption can result in decreased efficacy. A reduction in the variability of the absorption may result in drugs with lower dosing, reduced side effects and improved efficacy, safety and patient compliance.
The majority of conventional drug delivery technologies aimed at increasing bioavailability of compounds with low water solubility rely on reduction of the particle size of the drug substance. The figure below shows a comparison of different formulation technologies in terms of particle size.
